Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

MicroRNAs Are Regulators and Biomarkers of Bone Cancer Metastasis

By BiotechDaily International staff writers
Posted on 30 Oct 2013
Image: Researchers at Princeton University have found that microRNAs may serve as both therapeutic targets and predictors of metastasis. In this image, breast cancer cells (right) spread toward the hindlimb bone (left), using the host's own osteoclasts to continue their advance (Photo courtesy of Dr. Yibin Kang, Princeton University).
Image: Researchers at Princeton University have found that microRNAs may serve as both therapeutic targets and predictors of metastasis. In this image, breast cancer cells (right) spread toward the hindlimb bone (left), using the host's own osteoclasts to continue their advance (Photo courtesy of Dr. Yibin Kang, Princeton University).
Different groups of microRNAs (miRNAs) have been found to either inhibit or promote metastasis of cancer in the bone, which occurs in about 70% of patients with late-stage cancer.

Investigators at Princeton University (Princeton, NJ, USA) reported in the October 14, 2013, edition of the journal Cancer Cell that miR-141 and miR-219 inhibited metastasis by targeting osteoclast genes. Intravenous delivery of these miRNAs in vivo inhibited osteoclast activity and reduced osteolytic bone metastasis.

In contrast, serum levels of sICAM1 (soluble intracellular adhesion molecule) and two osteoclast miRNAs, miR-16 and miR-378, which were elevated in osteoclast differentiation, correlated with increased bone metastasis in mouse models.

"The tumor uses the osteoclasts as forced labor," said senior author Dr. Yibin Kang, professor of molecular biology at Princeton University. "We ultimately hope to extend mice experimentation to clinical trials. In the end, we want to help the patients."

The authors suggested that the findings published in the Cancer Cell paper establish miRNAs as potential therapeutic targets and clinical biomarkers of bone metastasis.

Related Links:

Princeton University



Channels

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.